To the Editor: In their Clinical Review, Dr Burt and colleagues1 assessed clinical applications of adult stem cell therapies
for nonmalignant diseases.
Not exact matches
The Bone Marrow and Stem Cell Transplant Program is expanding the use of this technique
for patients with solid tumors including neuroblastoma and brain tumors; a variety of high - risk hematologic
diseases, such as thalassemia major and transfusion - dependent sickle cell
disease; and other
nonmalignant diseases.
The «new RECA» expands the universe of workers eligible
for federal compensation to include open - pit uranium miners, uranium millworkers and ore - hauling truck drivers; expands the list of compensatory illnesses and causes of death to include several cancers in addition to lung cancer, certain
nonmalignant respiratory
diseases, and
diseases of the kidney.
These advances make it possible
for half - identical bone marrow transplants to be used in
nonmalignant diseases, such as aplastic anemia, lupus, and sickle cell anemia.